Gilead's Trodelvy Falls Short of Phase III Trial Primary Endpoint of Improved Overall Survival in NSCLC
The EVOKE-01 trial compared Trodelvy with docetaxel for the treatment of patients with metastatic or advanced non-small cell lung cancer who progressed on or following platinum-based chemotherapy and checkpoint inhibitor therapy.
